ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Ahypoxia-related signature enhances the prediction of the prognosis in hepatocellular carcinoma patients and correlates with sorafenib treatment response

Jiang, Hong-Ye; Ning, Gang; Wang, Yen-Sheng; Lv, Wei-Biao*南方医科大学; 1
American Journal of Translational Research2020
14被引7阅读
引用收藏
分享

摘要

Hepatocellular carcinoma (HCC) is one of the leading cancer death and is the primary malignancy of the liver. Tumor hypoxia is the stressor that is involved in tumorigenesis and significantly increased the aggressiveness of HCC. Here, we systematically analyzed the expression profiles and prognostic values of 84 hypoxia associated genes in HCC. mRNA expression of 84 hypoxia associated genes and clinical parameters of HCC patients were downloaded from TCGA, GSE14520, GSE109211 and ICGC. Consensus clustering analysis was performed for unsupervised classes on the basis of 84 hypoxia associated genes. Univariate and LASSO analysis were used to develop the risk signature. A risk signature was developed, including the expression of APEX1, ATR, CTSA, DNAJC5, ENO1, EPO, HMOX1, LDHA, NDRG1, and PER', and found to be significantly related with OS and DFS of HCC patients. We stratified HCC patients into the high-risk group and low-risk group by means of the risk signature. Patients of high-risk group had shorter OS and DFS, while that of the low-risk group had longer OS and DFS. The risk signature showed better predictive efficiency than the TNM staging in predicting OS and DFS. Also, macrophage MO cells, regulatory T cells, and neutrophils were found to be significantly enriched in patients of high-risk group. Next, we validated the discrimination and prognostic value of the risk signature in GSE14520 and the ICGC HCC cohort. Finally, significantly lower risk scores were found in sorafenib treatment responders of GSE109211 cohort, and the AUC for predicting sorafenib treatment response was 0.881. In conclusion, a risk signature developed with the expression of 10 hypoxia associated genes improved the prognosis prediction of HCC and correlated with sorafenib treatment response.

学科与关键词

关键词
HypoxiaHCCrisk signatureprognosissorafenibtreatment response
相关
加载中…
  • Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma
    Zeng, Fanhong; Zhang, Yue; Han, Xu; Zeng, Min; Gao, Yi*; Weng, Jun*Computational and Structural Biotechnology Journal, 2021, 19: 2775-2789.被引 16
  • Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response
    Jiang, Hongye; Ning, Gang; Wang, Yensheng; Lv, Weibiao*DISEASE MARKERS, 2021, 2021: 5576683.被引 23
  • A Comprehensive Prognostic and Immunological Analysis of a New Three-Gene Signature in Hepatocellular Carcinoma
    Liu, Jun; Lu, Jianjun; Li, Wenli*2021, 2021: 5546032.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
American Journal of Translational Research
发表日期
2020
卷期
第 12 卷, 第 12 期
页码
7762-7781
语言
ENGLISH
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2020M682626]; Wu Jieping Medical Foundation [320.6750.17528]

作者

  • J

    Jiang, Hong-Ye (第一作者)

    1 · southern med univ

  • N

    Ning, Gang

    1

查看全部 4 位作者收起作者
  • W

    Wang, Yen-Sheng

  • L

    Lv, Wei-Biao (通讯)

    1 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417